Literature DB >> 31298745

Characterization of Gut Microbiota, Bile Acid Metabolism, and Cytokines in Intrahepatic Cholangiocarcinoma.

Xiaodong Jia1, Shanshan Lu1, Zhen Zeng1, Qingyan Liu1, Zheng Dong1, Yan Chen1, Zhenyu Zhu2, Zhixian Hong3, Ting Zhang1, Guifang Du1, Jiao Xiang1, Dawei Wu1, Wenlin Bai1, Bin Yang1, Yinyin Li1, Jiagan Huang1, Haiyang Li4, Rifaat Safadi5, Yinying Lu1,6.   

Abstract

Intrahepatic cholangiocarcinoma (ICC), a type of bile duct cancer, has a high mortality rate. Gut microbiota, bile acid (BA) metabolism, and cytokines have not been characterized in patients with ICC, and better noninvasive diagnostic approaches for ICC are essential to be established. Therefore, in this study we aimed to improve our understanding of changes in gut microbiota, BA metabolism, and cytokines in patients with ICC. We found that the α-diversities and β-diversities of ICC were highest and that the abundances of four genera (Lactobacillus, Actinomyces, Peptostreptococcaceae, and Alloscardovia) were increased in patients with ICC compared with those in patients with hepatocellular carcinoma or liver cirrhosis and in healthy individuals. The glycoursodeoxycholic acid and tauroursodeoxycholic acid (TUDCA) plasma-stool ratios were obviously increased in patients with ICC. Furthermore, the genera Lactobacillus and Alloscardovia that were positively correlated with TUDCA plasma-stool ratios were combined to discriminate ICC from the other three diseases. Vascular invasion (VI) frequently led to a poor prognosis in patients with ICC. Compared with patients with ICC without VI, patients with VI had a greater abundance of the family Ruminococcaceae, increased levels of plasma interleukin (IL)-4 and six conjugated BAs, and decreased levels of plasma IL-6 and chenodeoxycholic acid. A positive correlation between plasma taurocholic acid and IL-4 was observed in patients with ICC. Plasma TUDCA was negatively correlated with the abundance of the genus Pseudoramibacter and the survival time of patients with ICC, but had no effect on tumor size, as determined in two murine tumor models.
Conclusion: In this study, we identified some biomarkers, including gut microbiota, BAs and inflammatory cytokines, for the diagnosis of ICC and prediction of VI in patients with ICC.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31298745     DOI: 10.1002/hep.30852

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  26 in total

1.  Clinical relevance of the relationship between changes in gut microbiota and bile acid metabolism in patients with intrahepatic cholangiocarcinoma.

Authors:  Elisa Herraez; Marta R Romero; Rocio I R Macias; Maria J Monte; Jose J G Marin
Journal:  Hepatobiliary Surg Nutr       Date:  2020-04       Impact factor: 7.293

Review 2.  Gut microbiome in gastrointestinal cancer: a friend or foe?

Authors:  Yang Liu; Yoshifumi Baba; Takatsugu Ishimoto; Xi Gu; Jun Zhang; Daichi Nomoto; Kazuo Okadome; Hideo Baba; Peng Qiu
Journal:  Int J Biol Sci       Date:  2022-06-21       Impact factor: 10.750

Review 3.  Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy.

Authors:  Roseanna C Wheatley; Elaine Kilgour; Timothy Jacobs; Angela Lamarca; Richard A Hubner; Juan W Valle; Mairéad G McNamara
Journal:  Br J Cancer       Date:  2021-10-18       Impact factor: 9.075

Review 4.  The microbiome, genetics, and gastrointestinal neoplasms: the evolving field of molecular pathological epidemiology to analyze the tumor-immune-microbiome interaction.

Authors:  Kosuke Mima; Keisuke Kosumi; Yoshifumi Baba; Tsuyoshi Hamada; Hideo Baba; Shuji Ogino
Journal:  Hum Genet       Date:  2020-11-12       Impact factor: 4.132

5.  Microbial Characteristics of Common Tongue Coatings in Patients with Precancerous Lesions of the Upper Gastrointestinal Tract.

Authors:  Xiaoyu Kang; Bin Lu; Pan Xiao; Zhaolai Hua; Rui Shen; Jianping Wu; Juan Wu; Zhenfeng Wu; Chun Cheng; Junfeng Zhang
Journal:  J Healthc Eng       Date:  2022-04-18       Impact factor: 3.822

Review 6.  The gut-liver axis: host microbiota interactions shape hepatocarcinogenesis.

Authors:  Maruhen A D Silveira; Steve Bilodeau; Tim F Greten; Xin Wei Wang; Giorgio Trinchieri
Journal:  Trends Cancer       Date:  2022-03-21

Review 7.  Linking Gut Microbiome and Lipid Metabolism: Moving beyond Associations.

Authors:  Santosh Lamichhane; Partho Sen; Marina Amaral Alves; Henrique C Ribeiro; Peppi Raunioniemi; Tuulia Hyötyläinen; Matej Orešič
Journal:  Metabolites       Date:  2021-01-15

8.  A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.

Authors:  Wenbo Zou; Zizheng Wang; Fei Wang; Lincheng Li; Rong Liu; Minggen Hu
Journal:  BMC Cancer       Date:  2021-05-25       Impact factor: 4.430

9.  A Predictive Model Based on the Gut Microbiota Improves the Diagnostic Effect in Patients With Cholangiocarcinoma.

Authors:  Tan Zhang; Sina Zhang; Chen Jin; Zixia Lin; Tuo Deng; Xiaozai Xie; Liming Deng; Xueyan Li; Jun Ma; Xiwei Ding; Yaming Liu; Yunfeng Shan; Zhengping Yu; Yi Wang; Gang Chen; Jialiang Li
Journal:  Front Cell Infect Microbiol       Date:  2021-11-23       Impact factor: 5.293

Review 10.  Current Advances in Basic and Translational Research of Cholangiocarcinoma.

Authors:  Keisaku Sato; Leonardo Baiocchi; Lindsey Kennedy; Wenjun Zhang; Burcin Ekser; Shannon Glaser; Heather Francis; Gianfranco Alpini
Journal:  Cancers (Basel)       Date:  2021-07-01       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.